Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors

LIBRETTO-001 cohort 7: A single-arm, phase 2 study of neoadjuvant selpercatinib in patients with resectable stage IB-IIIA RET fusion-positive NSCLC.

(2022) Ravi Rajaram et al.   JOURNAL OF CLINICAL ONCOLOGY

A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress).

(2022) Nathan A. Pennell et al.   JOURNAL OF CLINICAL ONCOLOGY

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

(2022) Vivek Subbiah et al.   NATURE MEDICINE

1656P Durable efficacy of selpercatinib in patients (pts) with medullary thyroid cancer (MTC): Update of the LIBRETTO-001 trial

(2022) M. Kroiss et al.   ANNALS OF ONCOLOGY

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

(2022) Alexander Drilon et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

(2022) Vivek Subbiah et al.   LANCET ONCOLOGY

An early look at selective RET inhibitor resistance: new challenges and opportunities

(2021) Jessica J. Lin et al.   BRITISH JOURNAL OF CANCER

20 years of precision medicine in oncology

(2021) The Lancet   LANCET

Advances in Targeting RET-Dependent Cancers

(2020) Vivek Subbiah et al.   Cancer Discovery

The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models.

(2020) Alexander E. Drilon et al.   JOURNAL OF CLINICAL ONCOLOGY

Selpercatinib: First Approval

(2020) Anthony Markham   DRUGS

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

(2020) Lori J. Wirth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

(2020) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

(2020) V. Subbiah et al.   ANNALS OF ONCOLOGY

Mechanisms of receptor tyrosine kinase activation in cancer

(2018) Zhenfang Du et al.   Molecular Cancer

A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.

(2018) Alexander E. Drilon et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY